Results for this period
Third quarter1 January 2026 to 30 September 2026Non-consolidated (separate)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Net sales declined by ¥22.838 million year on year. In the regenerative medicine support business, net sales fell by ¥25.441 million and the operating loss widened by ¥21.173 million, while in the cell-sheet regenerative medicine business, net sales increased by ¥2.602 million and the operating loss narrowed by ¥36.187 million.
A description of material events and other matters is included. Regarding the first cell-sheet regenerative medicine product, which is in Phase 3 clinical trials, the company determined that there is significant uncertainty about whether approval will be obtained and the product monetized, creating circumstances that raise substantial doubt about the going-concern assumption. However, the notes regarding the going-concern assumption state: "There are no applicable matters."
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (separate) |
| Period Covered | 1 January 2026 to 30 September 2026 |
| Net Sales | 42 Millions of yen (YoY -35.0%) |
| Operating profit | -834 Millions of yen |
| Ordinary income | -835 Millions of yen |
| Profit attributable to owners of the parent | -910 Millions of yen |
| Net income per share | △¥23.51 |
| Equity ratio | End of the current fiscal period 83.0% / End of previous period 76.0% |
| Total assets | 1,819 Millions of yen |
| Net assets | 1,524 Millions of yen |
| Full-year earnings forecast | Net Sales 50 Millions of yen (YoY -40.2%) / Operating profit -1,225 Millions of yen / Ordinary income -1,234 Millions of yen / Net income -1,309 Millions of yen |
| Revision to Earnings Forecast | Net Sales Not disclosed → 50 Millions of yen / Operating profit Not disclosed → -1,225 Millions of yen / Ordinary income Not disclosed → -1,234 Millions of yen / Net income Not disclosed → -1,309 Millions of yen |
| Annual Dividend Forecast | 0 Yen → 0 Yen（0.0%） |
| Segment revenue | Regenerative medicine support business ¥37,944 thousand / Cell-sheet regenerative medicine business ¥4,477 thousand |
| Segment profit | Regenerative medicine support business ¥-100,725 thousand / Cell-sheet regenerative medicine business ¥-541,950 thousand |
| Depreciation and amortization | ¥0 thousand |
| Impairment loss | ¥74,773 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on reversal of subscription rights to shares ¥2,114 thousand / Extraordinary loss Impairment loss ¥74,773 thousand |
| Disclosure regarding the going concern assumption | A description of material events and other matters is included. Regarding the first cell-sheet regenerative medicine product, which is in Phase 3 clinical trials, the company determined that there is significant uncertainty about whether approval will be obtained and the product monetized, creating circumstances that raise substantial doubt about the going-concern assumption. However, the notes regarding the going-concern assumption state: "There are no applicable matters." |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | Between 1 October and 31 October 2026, 1,131 of the 25th Series Stock Acquisition Rights were exercised and 113,100 shares were issued. The total exercise price was ¥23.503 million, and the increase in capital was ¥11.774 million. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 39,539,819 shares |
| Treasury Shares at Period-End | 156 shares |
| Factors Behind Changes in Business Performance | Net sales declined by ¥22.838 million year on year. In the regenerative medicine support business, net sales fell by ¥25.441 million and the operating loss widened by ¥21.173 million, while in the cell-sheet regenerative medicine business, net sales increased by ¥2.602 million and the operating loss narrowed by ¥36.187 million. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company explained that it is working to strengthen its financial base through the exercise of the 25th Series Stock Acquisition Rights, continuously review costs, and advance its core businesses, namely the regenerative medicine support business and cell-sheet regenerative medicine business. It did not specify the reasons for the decline in revenue or the widening operating loss.